(UPDATED) MASTER DAPT, the latest and largest randomized clinical trial to tackle the conundrum of dual antiplatelet therapy (DAPT) duration in post-PCI patients at high risk for bleeding, indicates ...
Another trial has added to the movement towards shortening the duration of dual antiplatelet therapy (DAPT) after percutaneous coronary intervention (PCI). In the MASTER DAPT trial involving patients ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback